Cadence Secures Supply of Key Ingredient For Drug in Phase III Trials

12/6/08

San Diego’s Cadence Pharmaceuticals has entered into a long-term supply agreement with Solvay SA, a Belgian biotech giant, for the active ingredient in its Omnigard gel for treating wounds and burns. Cadence disclosed the deal in a filing with government regulators Friday, although financial terms were not revealed. If Cadence notifies Solvay after Omnigard’s phase III clinical trials that Cadence intends to file a new drug application, a related licensing agreement allows Cadence rights to a secondary source of the ingredient, omiganan pentahydrochloride

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.